




RealRate

PHARMACEUTICAL 2025

Virpax Pharmaceuticals Inc
Rank 221 of 225



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Virpax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virpax Pharmaceuticals Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1.5% points. The greatest weakness of Virpax Pharmaceuticals Inc is the variable Assets, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 2.8%, being 212% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	1,556
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,469
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	13
Other Revenues	0
Property and Equipment	0
Research and Development	5,819
Selling, General and Administrative Expense	6,261

Output Variable	Value in 1000 USD
Assets	1,556
Liabilities	2,469
Expenses	12,080
Revenues	0
Stockholders Equity	-914
Net Income	-12,067
Comprehensive Net Income	-12,067
BaseVar	8,059
ECR before Limited Liability	-699%
Economic Capital Ratio	2.8%